C0299792||aripiprazole
C0073393||risperidone
C0020514||hyperprolactinaemia
C0013072||double-blind
C0282440||randomised
C1706408||placebo-controlled trial
C0020514||Hyperprolactinaemia
C0879626||side-effect
C0087111||treatment
C0040615||antipsychotics
C0013072||double-blind
C1706408||placebo-controlled study
C0373706||prolactin levels
C0879626||side-effects
C0036341||schizophrenia
C0073393||risperidone
C0073393||risperidone
C0008976||trial
C0299792||Aripiprazole
C0806914||administered
C1277972||Serum prolactin
C0020514||Hyperprolactinaemia
C0033213||problems
C0004936||psychopathology
C0879626||side-effects
C0220825||evaluated
C0857016||Prolactin levels decreased
C0299792||aripiprazole
C0580441||Prolactin levels normalised
C0299792||aripiprazole
C0299792||Aripiprazole
C0184511||improved
C0242350||erectile dysfunction
C0004936||psychopathology
C0879626||side-effects
C0299792||aripiprazole
C0373706||prolactin levels
C0332293||treated with
C0073393||risperidone
C0004936||psychopathology
C0234133||extrapyramidal symptoms
C0087111||treatment
C0020514||hyperprolactinaemia
C0087111||treatment
C0040615||second-generation antipsychotics